Literature DB >> 17606704

Triggering tumor immunity through angiogenesis targeting.

Masahisa Jinushi1, Glenn Dranoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17606704     DOI: 10.1158/1078-0432.CCR-07-0880

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  5 in total

1.  Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells.

Authors:  Ofer Fainaru; Nava Almog; Chong Wing Yung; Kei Nakai; Martin Montoya-Zavala; Amir Abdollahi; Robert D'Amato; Donald E Ingber
Journal:  FASEB J       Date:  2009-12-14       Impact factor: 5.191

2.  Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

3.  Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival.

Authors:  A J Montero; C M Diaz-Montero; R E Millikan; J Liu; K-A Do; S Hodges; E Jonasch; B W McIntyre; P Hwu; N Tannir
Journal:  Ann Oncol       Date:  2009-06-18       Impact factor: 32.976

Review 4.  PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.

Authors:  Scott S Tykodi
Journal:  Onco Targets Ther       Date:  2014-07-25       Impact factor: 4.147

5.  Antitumor effects of recombinant antivascular protein ABRaA-VEGF121 combined with IL-12 gene therapy.

Authors:  Agnieszka Ciomber; Andrzej Smagur; Iwona Mitrus; Tomasz Cichoń; Ryszard Smolarczyk; Aleksander Sochanik; Stanisław Szala; Magdalena Jarosz
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-11-13       Impact factor: 4.291

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.